Share This Article:

Liraglutide as Add-on to Oral Antidiabetic Agents or Insulin in Routine Practice of Patients with Type 2 Diabetes

Abstract Full-Text HTML Download Download as PDF (Size:327KB) PP. 148-154
DOI: 10.4236/jdm.2014.42022    2,785 Downloads   3,738 Views   Citations

ABSTRACT

Aims: To evaluate in a real-word routine-care practice the effect of liraglutide as add-on treatment in type 2 diabetic patients treated with oral antidiabetic agents and/or insulin. Methods: A retrospective study from 3 outpatient clinics in Copenhagen, Denmark, of all patients (n = 534) initiating treatment with liraglutide. 346 patients were treated ≥3 months. Excluded from analysis were: 107 patients changing from exenatide and 83 due to lack of clinical response or adverse events. Results: In 149 patients liraglutide was add-on to oral antidiabetic agents, most often metformin plus sulfonylurea (n = 86). Mean follow-up: 7.3 ± 3.0 months. HbA1c reduction: 1.3% ± 1.5% (15 ± 16 mmol/mol) from a baseline of 8.7% ± 1.5% (71 ± 16 mmol/mol). Weight reduction: 3.5 ± 4.9 kg from 105.2 ± 21.3 kg. Sulfonylurea treatment was stopped/dose reduced in 57% of these patients. In 114 patients liraglutide was add-on to insulin. Mean follow-up: 7.0 ± 3.1 months. HbA1c reduction: 0.8% ± 1.2% (8 mmol/mol) from a baseline of 8.7% ± 1.5% (71 ± 16 mmol/mol). Weight reduction: 5.1 ± 4.9 kg from 109.2 ± 22.1 kg. Baseline insulin dose of 83 ± 59 U/day was reduced by 28 ± 36 U/day. Insulin therapy could be stopped in 19% of these patients. Conclusions: Effects on HbA1c and weight of liraglutide as add-on to oral antidiabetic agents were not different from results previously published in randomised trials. Adding liraglutide to existing insulin regimens is an attractive treatment strategy in obese type 2 diabetic patients.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Anholm, C. , Frandsen, H. , Sigfusson, E. , Vestergaard, H. and Madsbad, S. (2014) Liraglutide as Add-on to Oral Antidiabetic Agents or Insulin in Routine Practice of Patients with Type 2 Diabetes. Journal of Diabetes Mellitus, 4, 148-154. doi: 10.4236/jdm.2014.42022.

References

[1] Perry, C.M. (2011) Liraglutide: A Review of Its Use in the Management of Type 2 Diabetes Mellitus. Drugs, 71, 2347-2373. http://dx.doi.org/10.2165/11208110-000000000-00000
[2] Madsbad, S. (2009) Exenatide and Liraglutide: Different Approaches to Develop GLP-1 Receptor Agonists (Incretin-mimetics)—Preclinical and Clinical Results. Best Practice & Research Clinical Endocrinology & Metabolism, 23, 463-477. http://dx.doi.org/10.1016/j.beem.2009.03.008
[3] Holst, J.J. (2007) The Physiology of Glucagon-Like Peptide 1. Physiological Reviews, 87, 1409-1439. http://dx.doi.org/10.1152/physrev.00034.2006
[4] Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang-Christensen, M. and Knudsen, L.B. (2012) Liraglutide: Short-Lived Effect on Gastric Emptying—Long Lasting Effects on Body Weight. Diabetes, Obesity and Metabolism, 14, 531-538. http://dx.doi.org/10.1111/j.1463-1326.2012.01557.x
[5] Madsbad, S. (2012) Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Are Favourable to Glucagon-Like Peptide-1 (GLP-1) Agonists. European Journal of Internal Medicine, 23, 132-136.
http://dx.doi.org/10.1016/j.ejim.2011.11.003
[6] Flint, A., Kapitza, C. and Zdravkovic, M. (2013) The Once-Daily Human GLP-1 Analogue Liraglutide Impacts Appetite and Energy Intake in Patients with Type 2 Diabetes after Short-Term Treatment. Diabetes, Obesity and Metabolism, 15, 958-962. http://dx.doi.org/10.1111/dom.12108
[7] Niswender, K., Pi-Sunyer, X., Buse, J., Jensen, K.H., Toft, A.D., Russell-Jones, D., et al. (2013) Weight Change with Liraglutide and Comparator Therapies: An Analysis of Seven Phase 3 Trials from the Liraglutide Diabetes Development Programme. Diabetes, Obesity and Metabolism, 15, 42-54. http://dx.doi.org/10.1111/j.1463-1326.2012.01673.x
[8] Nauck, M., Brandle, M., Vaag, A., Colagiuri, S., Schmitz, O., Zdravkovic, M., et al. (2008) The Once-Daily Human GLP-1 Analogliraglutide Substantially Reduces HbA(1c) in Subjects with Type 2 Diabetes, Irrespective of HbA(1c) at Baseline. Diabetes, 57, A594.
[9] DeFronzo, R.A. (2009) Banting Lecture. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes, 58, 773-795.
http://dx.doi.org/10.2337/db09-9028
[10] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. (2012) Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 1364-1379.
[11] Hemmingsen, B., Christensen, L.L., Wetterslev, J., Vaag, A., Gluud, C., Lund, S.S., et al. (2012) Comparison of Metformin and Insulin versus Insulin Alone for Type 2 Diabetes: Systematic Review of Randomised Clinical Trials with Meta-Analyses and Trial Sequential Analyses. BMJ, 344, e1771.
[12] Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., Paul, S., et al. (2007) Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. The New England Journal of Medicine, 357, 1716-1730. http://dx.doi.org/10.1056/NEJMoa075392
[13] Rosenstock, J., Davies, M., Home, P.D., Larsen, J., Koenen, C. and Schernthaner, G. (2008) A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-On to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes. Diabetologia, 51, 408-416. http://dx.doi.org/10.1007/s00125-007-0911-x
[14] Buse, J.B., Bergenstal, R.M., Glass, L.C., Heilmann, C.R., Lewis, M.S., Kwan, A.Y., et al. (2011) Use of TWICE-Daily Exenatide in Basal Insulin-Treated Patients with Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine, 154, 103-112. http://dx.doi.org/10.7326/0003-4819-154-2-201101180-00300
[15] Evans, M., McEwan, P., O’Shea, R. and George, L. (2013) A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice. Diabetes Therapy, 4, 27-40. http://dx.doi.org/10.1007/s13300-012-0015-6
[16] Fadini, G.P., Simioni, N., Frison, V., Dal, P.M., Bettio, M., Rocchini, P., et al. (2013) Independent Glucose and Weight-Reducing Effects of Liraglutide in a Real-World Population of Type 2 Diabetic Outpatients. Acta Diabetologica, 50, 943-949. http://dx.doi.org/10.1007/s00592-013-0489-3
[17] Thong, K.Y., Jose, B., Sukumar, N., Cull, M.L., Mills, A.P., Sathyapalan, T., et al. (2011) Safety, Efficacy and Tolerability of Exenatide in Combination with Insulin in the Association of British Clinical Diabetologists Nationwide Exenatide Audit. Diabetes, Obesity and Metabolism, 13, 703-710. http://dx.doi.org/10.1111/j.1463-1326.2011.01393.x
[18] Levin, P., Wei, W., Wang, L., Pan, C., Douglas, D. and Baser, O. (2012) Combination Therapy with Insulin Glargine and Exenatide: Real-World Outcomes in Patients with Type 2 Diabetes. Current Medical Research and Opinion, 28, 439-446. http://dx.doi.org/10.1185/03007995.2012.654850
[19] Nayak, U.A., Govindan, J., Baskar, V., Kalupahana, D. and Singh, B.M. (2010) Exenatide Therapy in Insulin-Treated Type 2 Diabetes and Obesity. QJM: An International Journal of Medicine, 103, 687-694. http://dx.doi.org/10.1093/qjmed/hcq112
[20] Pawaskar, M., Li, Q., Hoogwerf, B.J., Reynolds, M.W., Lee, L.J. and Fonseca, V. (2012) Clinical Outcomes of Concomitant Therapy of Exenatide Twice Daily and Basal Insulin in Patients with Type 2 Diabetes Mellitus: A Retrospective Database Analysis in the United States. Endocrine Practice, 18, 700-711. http://dx.doi.org/10.4158/EP11367.OR
[21] Sheffield, C.A., Kane, M.P., Busch, R.S., Bakst, G., Abelseth, J.M. and Hamilton, R.A. (2008) Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus. Endocrine Practice, 14, 285-292. http://dx.doi.org/10.4158/EP.14.3.285
[22] Viswanathan, P., Chaudhuri, A., Bhatia, R., Al-Atrash, F., Mohanty, P. and Dandona, P. (2007) Exenatide Therapy in Obese Patients with Type 2 Diabetes Mellitus Treated with Insulin. Endocrine Practice, 13, 444-450. http://dx.doi.org/10.4158/EP.13.5.444
[23] Yoon, N.M., Cavaghan, M.K., Brunelle, R.L. and Roach, P. (2009) Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice over Two Years in an Academic Endocrinology Outpatient Setting. Clinical Therapeutics, 31, 1511-1523. http://dx.doi.org/10.1016/j.clinthera.2009.07.021
[24] Davis, S.N., Johns, D., Maggs, D., Xu, H., Northrup, J.H. and Brodows, R.G. (2007) Exploring the Substitution of Exenatide for Insulin in Patients with Type 2 Diabetes Treated with Insulin in Combination with Oral Antidiabetes Agents. Diabetes Care, 30, 2767-2772.
http://dx.doi.org/10.2337/dc06-2532
[25] Thong, K.Y., Jose, B., Blann, A.D., Cull, M.L., Mills, A.P., Sathyapalan, T., et al. (2011) Response at 3 Months to Insulin Dose Decisions Made at Exenatide Initiation in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit. Diabetes Research and Clinical Practice, 93, e87-e91. http://dx.doi.org/10.1016/j.diabres.2011.05.015
[26] Riddle, M.C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., et al. (2013) Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L). Diabetes Care, 36, 2489-2496. http://dx.doi.org/10.2337/dc12-2454

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.